Biomark Capital Management Co. LLC (David S. Wetherell)

Person Signing this Report on Behalf of Reporting Manager:

The filing of this report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g), or 16(a) under the Securities Exchange Act of 1934, as amended, and the rules thereunder, or for any other purpose, that the Reporting Manager or any other person (including Other Managers or Other Included Managers named herein) is the beneficial owner of any securities. Biomark Capital Management Co. LLC, a Delaware limited liability company (the "Management Company"), is an institutional investment manager which, for the purposes of Section 13(f) of the Securities Exchange Act of 1934 and the rules promulgated thereunder ("Section 13(f)"), exercises investment discretion with respect to certain securities positions held directly and indirectly by Biomark Capital Fund IV LP, a Delaware limited partnership (the "Fund"). David S. Wetherell, an individual ("Wetherell") and Biomark Capital Fund IV GP LLC, a Delaware limited liability company (the "General Partner"), may each be deemed to exercise investment discretion over the securities reported on this Form 13F for purposes of Section 13(f). Certain of the security positions reported by the Management Company are also being reported by Wetherell and the General Partner. Also, 603,364 shares of common stock of Juno Therapeutics, Inc. reported by the Management Company are held by a majority owned portfolio company of the Fund. Each of the Management Company, the General Partner and Wetherell disclaims beneficial ownership of the shares reported on this Form 13F by the Management Company except to the extent of any pecuniary interest therein.

Other Included Managers (2):